<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03818568</url>
  </required_header>
  <id_info>
    <org_study_id>2015-785-038</org_study_id>
    <nct_id>NCT03818568</nct_id>
  </id_info>
  <brief_title>Ketoanalogues and Stage 4 CKD</brief_title>
  <official_title>Restriction of Proteins in the Diet and Supplementation With Ketoanalogues to Prevent Disease Progression in Patients With Stage 4 Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators intend to analyze diets restricted in protein and supplemented with
      ketoanalogues of essential amino acids, to slow the progress of renal damage and improve
      nutritional status in diabetic patients over 60 years with stage 4 chronic kidney disease.

      Evey 2 months, evaluations will be performed of renal function (creatinine clearance, serum
      cysteine, proteinuria) and nutritional status (subjective global evaluation,dominant had
      pressure strength, body composition by bioelectric impedance, serum transferrin, serum
      prealbumin and serum aminogram) for a follow-up period of 2 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glomerular filtration</measure>
    <time_frame>2 years</time_frame>
    <description>Speed of reduction in glomerular filtration measured by cysteine C clearance and the need for dialysis glomerular filtration &lt;15 mL/min/1.73 m2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comorbidities</measure>
    <time_frame>2 years</time_frame>
    <description>measure of frequency and number of comorbidities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>2 years</time_frame>
    <description>measure of number and length of hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>2 years</time_frame>
    <description>measure of incidence of mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Stage 4 Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>ketoanalogues of essential amino acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ketoanalogues of essential amino acids</intervention_name>
    <description>Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>ketoanalogues of essential amino acids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diabetic nephropathy in stage 4 chronic kidney disease

          -  Patients in pre-dialysis

          -  Patients with signed informed consent forms.

        Exclusion Criteria:

          -  Patients who have received Ketosteril previously

          -  Patients participating in other intervention studies

          -  Pregnant women

          -  Patients with background of renal transplant

          -  Patients with cancer, HIV, seropositive for hepatitis B or C or receiving
             immunosuppressors, hypercalcemia

          -  Intolerance of Ketosteril ingredients

          -  Hereditary disorders in amino acid metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Unidad de Investigación Médica en Enfermedades Nefrológicas, Instituto Mexicano del Seguro Social</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <zip>06722</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Ramon Paniagua, PhD</last_name>
      <phone>56276900</phone>
      <phone_ext>21371</phone_ext>
      <email>jramonpaniaguas@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Maria de Jesus Ventura-Garcia, MSc</last_name>
      <phone>56276900</phone>
      <phone_ext>21371</phone_ext>
      <email>maria.ventuga@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ramon Paniagua, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catarina Munguia-Miranda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria de Jesus Ventura-Garcia, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2019</study_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Jose Ramon Paniagua Sierra</investigator_full_name>
    <investigator_title>Chief investigator</investigator_title>
  </responsible_party>
  <keyword>chronic kidney disease</keyword>
  <keyword>ketoanalogue</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

